Roberto J. Firpi

147 - VOLIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: AN ADAPTIVE, RANDOMIZED, PLACEBOCONTROLLED PHASE 2B TRIAL (VANTAGE): 28-WEEK INTERIM RESULTS

Michael A. Heneghan, Mitchell L. Shiffman, Debra Weinstein, Victor Ankoma-Sey et autres

OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results

Michael Heneghan, Mitchell Shiffman, Debra F. Weinstein, Victor Ankoma‐Sey et autres

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases

Ethan M. Weinberg, Huy Ngoc Trinh, Roberto J. Firpi, Kalyan Ram Bhamidimarri et autres

us (code pays fourni par la source)

1472-P: Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus

Kenneth J. Cusi, Michael Roden, Alfred Sidney Barritt, Roberto J. Firpi et autres

Nonalcoholic fatty liver disease (NAFLD), including its severe form known as steatohepatitis or NASH, are increasingly common in patients with type 2 diabetes mellitus (T2DM) and can progress to cirrhosis. However, there is limited information on their comorbid medical conditions in “real …

Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation

Andreas Giovanni Zori, Media N. Ismael, Alpna R. Limaye, Roberto J. Firpi et autres

OBJECTIVE: The objective of this study was to compare posttransplant outcomes in patients undergoing bridging locoregional therapy (LRT) with Y-90 transarterial radioembolization (TARE) based protocol compared with transarterial chemoembolization based protocol for hepatocellular carcinoma (HCC) prior liver transplantation (LT). MATERIALS AND METHODS: …

us, gb (code pays fourni par la source)

Tu1568 – Non-Invasive Testing of Liver Stiffness Can Effectively Identify Portal Hypertension in Patients with Advanced Fibrosis from Nafld

A. El Ouni, Joydeep Chakraborty, Tiffany Lambrou, Chelsea C. Jacobs et autres

Tu1573 – Transient Elastography Accurately Predicts Advanced Fibrosis (F3-F4) in Nafld Patients: is It Time to Move Away from Liver Biopsy?

Joydeep Chakraborty, A. El Ouni, Tiffany Lambrou, Chelsea C. Jacobs et autres

THU-329-Opioid use is common in patients with non-alcoholic fatty liver disease and associated with severity of liver disease, hepatic encephalopathy and psychiatric comorbidities

Andrew M. Moon, Roberto J. Firpi, Vandana Khungar, Justin Thomas Kupec et autres

THU-345-Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD

Ethan M. Weinberg, Huy Ngoc Trinh, Roberto J. Firpi, Kalyan Ram Bhamidimarri et autres

EARLY AND LATE HEART FAILURE POST-LIVER TRANSPLANTATION, PREDICTORS, AND OUTCOMES

Mohammad A. Al‐Ani, Sahil Prasada, A. El Ouni, Ameet Patel et autres

us (code pays fourni par la source)

Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) With and Without Type 2 Diabetes Mellitus (T2DM)

Kenneth J. Cusi, Alfred Sidney Barritt, Virginia Clark, Roberto J. Firpi et autres

Nonalcoholic Fatty Liver Disease (NAFLD), ranging from simple steatosis to its more severe form, steatohepatitis (NASH), is an increasingly common problem in patients with T2DM and is associated with progression to cirrhosis and extrahepatic complications (i.e., cardiovascular disease [CVD]). There is limited …

Su1509 - High Rates of Cardiovascular Events in NAFLD Patients: Real World Evidence from Target-NASH

Arun Jayant Sanyal, Kenneth J. Cusi, Roberto J. Firpi, Norman Gitlin et autres